BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25286759)

  • 21. The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate.
    Hall WA; Nickleach DC; Master VA; Prabhu RS; Rossi PJ; Godette K; Cooper S; Jani AB
    Cancer; 2013 Sep; 119(18):3272-9. PubMed ID: 23818401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
    Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a new outcome prediction model for Chinese patients with penile squamous cell carcinoma based on preoperative serum C-reactive protein, body mass index, and standard pathological risk factors: the TNCB score group system.
    Li ZS; Chen P; Yao K; Wang B; Li J; Mi QW; Chen XF; Zhao Q; Li YH; Chen JP; Deng CZ; Ye YL; Zhong MZ; Liu ZW; Qin ZK; Lin XT; Liang WC; Han H; Zhou FJ
    Oncotarget; 2016 Apr; 7(15):21023-33. PubMed ID: 26980738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy.
    Sevcenco S; Mathieu R; Baltzer P; Klatte T; Fajkovic H; Seitz C; Karakiewicz PI; Rouprêt M; Rink M; Kluth L; Trinh QD; Loidl W; Briganti A; Scherr DS; Shariat SF
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):163-7. PubMed ID: 26810014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
    Jain S; Lyons CA; Walker SM; McQuaid S; Hynes SO; Mitchell DM; Pang B; Logan GE; McCavigan AM; O'Rourke D; McArt DG; McDade SS; Mills IG; Prise KM; Knight LA; Steele CJ; Medlow PW; Berge V; Katz B; Loblaw DA; Harkin DP; James JA; O'Sullivan JM; Kennedy RD; Waugh DJ
    Ann Oncol; 2018 Jan; 29(1):215-222. PubMed ID: 29045551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
    Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
    Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.
    Tian R; Zhang F; Sun P; Wu J; Yan H; Wu AR; Zhang M; Jiang YL; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
    Oncotarget; 2016 Oct; 7(41):67485-67494. PubMed ID: 27528228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer.
    Liao SG; Cheng HH; Lei Y
    Oncol Res Treat; 2016; 39(5):266-71. PubMed ID: 27174032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-reactive Protein Is a Predictor of Prognosis of Prostate Cancer: A Systematic Review and Meta-Analysis.
    Liao DW; Hu X; Wang Y; Yang ZQ; Li X
    Ann Clin Lab Sci; 2020 Mar; 50(2):161-171. PubMed ID: 32366552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels.
    Lin ZY; Liang ZX; Zhuang PL; Chen JW; Cao Y; Yan LX; Yun JP; Xie D; Cai MY
    BMC Cancer; 2016 Oct; 16(1):792. PubMed ID: 27733196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients.
    Graff JN; Beer TM; Liu B; Sonpavde G; Taioli E
    Clin Genitourin Cancer; 2015 Aug; 13(4):e217-e221. PubMed ID: 25735198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
    Gakis G; Todenhöfer T; Renninger M; Schilling D; Sievert KD; Schwentner C; Stenzl A
    BJU Int; 2011 Dec; 108(11):1800-5. PubMed ID: 21507193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer.
    Wei B; Liang J; Hu J; Mi Y; Ruan J; Zhang J; Wang Z; Hu Q; Jiang H; Ding Q
    Med Sci Monit; 2017 Aug; 23():4192-4204. PubMed ID: 28855498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative serum C-reactive protein levels and postoperative survival in patients with esophageal squamous cell carcinoma: a propensity score matching analysis.
    Huang W; Wu L; Liu X; Long H; Rong T; Ma G
    J Cardiothorac Surg; 2019 Sep; 14(1):167. PubMed ID: 31533862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
    Troppan KT; Schlick K; Deutsch A; Melchardt T; Egle A; Stojakovic T; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Pichler M
    Br J Cancer; 2014 Jul; 111(1):55-60. PubMed ID: 24874478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
    Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
    BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy.
    Xia WX; Ye YF; Lu X; Wang L; Ke LR; Zhang HB; Roycik MD; Yang J; Shi JL; Cao KJ; Guo X; Xiang YQ
    PLoS One; 2013; 8(10):e76958. PubMed ID: 24130817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis.
    Liu ZQ; Chu L; Fang JM; Zhang X; Zhao HX; Chen YJ; Xu Q
    Asian J Androl; 2014; 16(3):467-71. PubMed ID: 24589465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.